| Literature DB >> 35937777 |
Aveline Hijlkema1, Caroline Roozenboom2, Marco Mensink1, Johannes Zwerver3,4.
Abstract
Background: Tendinopathy is a painful condition that is prevalent in athletes as well as the general human population, and whose management is challenging. Objective: This systematic review aimed to evaluate the impact of nutrition on the prevention and treatment of tendinopathy.Entities:
Keywords: Tendon; collagen; diet; supplements; tendinopathy
Mesh:
Year: 2022 PMID: 35937777 PMCID: PMC9354648 DOI: 10.1080/15502783.2022.2104130
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 4.948
Figure 1.PRISMA flow diagram of the study selection process.
Details of the studies examining exposure to the habitual diet (n = 5).
| Study | Design | Aim | Population | Nutritional exposure | Outcome measure(s) | Results | Conclusion |
|---|---|---|---|---|---|---|---|
| Hjerrild et al. (2019) [31] | Cross-sectional study | To investigate the effects of life-long physical activity on skin autofluorescence (SAF) and AT structure, and to determine if SAF and tendon structure are influenced by dietary factors | 182 athletes + 24 sedentary persons (54 ±18 y, male) | Diet (fruit, vegetables, fish, bread, cereals, coffee, wine, beer, liqueurs, total fluid, pure water) as well as overall dietary pattern (Western vs. Mediterranean) currently and during youth | Anteroposterior AT thickness (USI) | None of the dietary parameters was a significant predictor of AT thickness | Diet did not affect AT thickness |
| Jain et al. (2018) [29] | Prospective cohort study | To assess predictors of better shoulder pain and function after surgery | 50 patients with symptomatic RC tears undergoing operative treatment (59 ±9 y, 62% male) | Alcohol (habitual consumption <2-3/month vs. >1-2/week) | Shoulder pain and function (SPADI) at 3, 6, 12 and 18 months follow-up | Those consuming alcohol >1-2 times/week had lower SPADI scores (less shoulder pain and better function) than those consuming alcohol <2-3 times/month (p = 0.017) | Alcohol use is a longitudinal predictor of pain and functional outcomes after operative treatment for RC tears |
| Owens et al. (2013) [30] | Prospective cohort study | To prospectively identify risk factors for the development of lower extremity tendinopathy and plantar fasciitis in United States military personnel | 80,106 US active-duty military personnel (70.1% male) | Alcohol (none vs. light/moderate/heavy) | Risk of AT and PT tendinopathy (OR) | Moderate weekly alcohol consumption was marginally associated with increased risk for AT tendinopathy (OR = 1.33 (1.00-1.76), but not for PT tendinopathy (OR = 0.93 (0.71-1.21)) | Alcohol consumption is a potentially modifiable risk factor associated with AT tendinopathy |
| Passaretti et al. (2016) [33] | Case-control study | To investigate the association between alcohol consumption and RC tears | 249 patients treated arthroscopically for RC repair + 356 controls without RC tears (cases: 64 (54-78) y, 56% male; controls: 66 (58-82) y, 52% male) | Alcohol (nondrinkers vs. moderate/excessive drinkers) | Risk of RC tears (OR) | Significant risks of RC tears for excessive drinkers (men: OR = 1.7, p = 0.04; women: OR = 1.9, p = 0.04) | Long-term alcohol intake is a significant risk factor for onset and severity of rotator cuff tears |
| Rechardt et al. (2010) [32] | Cross-sectional study | To assess the associations of lifestyle factors, metabolic factors and carotid intima-media thickness with shoulder pain and chronic (>3 months) RC tendinitis. | 6237 participants (male: 50.8 y; female: 52.9 y, 46% male) | Alcohol (none/light/moderate/heavy) | Risk of RC tendinitis (OR) | Alcohol consumption was not associated with chronic RC tendinitis in either gender (data not shown) | (no conclusion with regard to alcohol) |
AT, Achilles tendon; CG, control group; OR, odds ratio; PT, patellar tendon; RC, rotator cuff; SPADI, Shoulder Pain and Disability Index; TG, treatment group; USI, ultrasound imaging
Details of the studies examining exposure to dietary supplements (n = 14).
| Study | Design | Aim | Population | Nutritional exposure | Concurrent exposure | Comparator | Outcome measure(s) | Results | Conclusion |
|---|---|---|---|---|---|---|---|---|---|
| Arquer et al. (2014) [44] | Non-comparative intervention study | To evaluate the efficacy and safety of a nutritional supplement on the clinical and structural evolution of AT, PT and LET tendinopathies | 98 tendinopathy patients, AT (n = 32): 49.2 ±3.64 y; PT (n = 32): 47.7 ±1.69 y; LET (n = 34): 39.0 ±2.44 y, both sexes | 3 capsules Tendoactive (mucopolysaccharides (435 mg), type I collagen (75 mg), vitamin C (60 mg)) per day for 90 consecutive days | None | Pre-measurements | Pain intensity at rest and when active (VAS); joint function (VISA-A/VISA-P/PRTEE); tendon cross-sectional thickness (USI) | After 90 days: Pain at rest decreased by 80% (AT), 71% (PT) and 91% (LET) (p <0.001). Pain when active decreased by 82% (AT), 73% (PT) and 81% (LET) (p <0.001). Functional scores improved by 38% (AT), 46% (PT) and 77% (LET) (p <0.001). Thickness reduced by 12% (AT), 10% (PT) and 20% (LET) (p <0.05). | Administration of Tendoactive is effective for improving the clinical symptoms and structural evolution of tendinopathies |
| Balius et al. (2016) [36] | RCT | To determine the additional benefit of mucopolysaccharides, collagen and vitamin C (MCVC) to a physical therapy program in patients with AT tendinopathy | 58 reactive or degenerative AT tendinopathy patients (18-70 y, both sexes) | 3 capsules MCVC (mucopolysaccharides (435 mg), type I collagen (75 mg), vitamin C (60 mg)) per day for 3 months | Eccentric training (EC+MCVC) or passive stretching (PS+MCVC) | Eccentric training only (EC) | VISA-A; pain at rest and during activity (VAS); tendon bilateral thickness (USI) | After 12 weeks: Statistically and clinically significant improvement in VISA-A scores in all groups without between-group effect (p >0.1). VAS scores decreased in all groups with a difference for pain at rest between PS+MCVC (−3.7(0.8) and EC (−2.7(1.3), p <0.05). Bilateral thickness remained constant in EC and EC+MCVC, and reduced in PS+MCVC (−0.63(0.3) mm, p <0.05). | MCVC seems to be therapeutically useful for the management of tendinopathies |
| Praet et al. (2019) [39] | RCT (cross-over) | To investigate whether oral supplementation of specific collagen peptides improves symptoms and tendon vascularization in patients with chronic mid-portion AT tendinopathy in combination with structured exercise | 20 mid-portion AT tendinopathy patients (44 ±8 y, 65% male) | Two daily sachets Tendoforte (2.5 g hydrolyzed specific collagen peptides) for 3 months | Eccentric and running exercises for 6 months | Placebo + eccentric and running exercises for 6 months | Pain and functional limitations (VISA-A); vascularization (USI) | The group receiving the supplement in the first 3 months improved by 12.6 (9.7-15.5) in the supplemental phase and 5.9 (2.8-9.0) in the placebo phase. The other group improved by 5.3 (2.3-8.3) and 17.7 (14.6-20.7). There was a difference between groups in evolution of the VISA-A scores over time (p <0.0001). No difference in vascularization between groups. | Supplementation of specific collagen peptides may accelerate the clinical benefits of exercise program in AT patients. |
| Vitali (2019) [43] | Non-randomized controlled study | To determine the efficacy of Extracorporeal Shock Wave Therapy (ESWT) in combination with the dietary supplement Tendisulfur Forte in the treatment of shoulder, LET and AT tendinopathies | 90 AT, shoulder or LET tendinopathies (39-69 y, 50% male) | Tendisulfur Forte (containing methyl-sulfonyl-methane (MSM), hydrolyzed swine collagen (Type I and Type II), L-arginine and L-lysine, vitamin C, chondroitin sulfate, glucosamine, Curcuma longa extracted to obtain curcuminoids, dry Boswellia serrata extracted to obtain acetyl-11-keto-b-boswellic acid (AKBA), and myrrh) 2x day for 1 month, 1x day for 1 month | ESWT | ESWT | Pain (VAS); clinical functional evaluation (VISA-A, UCLA shoulder score, MEPS) | After 60 days: UCLA scores were higher in TG [ | Combined treatment of ESWT and oral supplementation leads to a faster recovery and better outcomes of AT, shoulder and LET tendinopathy. |
| Merolla et al. (2015) [35] | RCT | To assess the analgesic effect of a dietary supplement containing Boswellia serrata and Curcuma longa in a population of subjects with full-thickness SSP tendon tear treated arthroscopically | 100 patients who underwent surgical SSP tendon repair (TG: 53.3 ±7.6 y, 54% male; CG: 55.4 ±9.4 y, 56% male) | Two daily sachets for 15 days, 1 sachet Tendisulfur (methyl-sulfonyl-methane, type I and II collagen, glycosaminoglycans, L-arginine, L-lysine, Boswellia serrata dry extract titrated to 30% inacetyl-1 1-keto-B-boswellic acid, Curcuma longa dry extract titrated to 95% curcuminoids) for 45 days | Conventional analgesic therapy | Placebo + conventional analgesic therapy | Overall pain, and pain at night, during activity and at rest (VAS); CMS; shoulder function (SST) | Lower overall and night pain scores in TG compared to CG at week 1 (p = 0.0477, p = 0.0113), but not for other pain scores or subsequent time points (p >0.05). CMS in TG (60.3 ±8.6) was not different from CG (59.3 ±8.8, p = 0.884) after 12 weeks or 24 weeks (71.6 ±8.1 vs. 69.9 ±7.2, p = 0.352). SST in TG (7.7 ±1.8) was not different from CG (6.9 ±2.7, p = 0.523) after 12 weeks or after 24 weeks (8.2 ±1.7 vs. 8.1 ±0.9, p = 0.292) | Tendisulfur alleviated short and partially mid-term pain after SSP tendon repair, while long-term pain was unchanged. |
| Gumina et al. (2012) [34] | RCT | To determine whether the intake of an oral integrator might mitigate shoulder pain and improve repair integrity of RC shoulder tear after arthroscopic repair | 87 RC patients who underwent surgical repair (47-69 y, 48% male) | Two daily sachets Tenosan (arginine-L-alpha-ketoglutarate, methyl-sulfonyl-methane, hydrolyzed type I collagen and bromelain) for 3 months starting from postoperative day 1 | Motion and strengthening exercises | Motion and strengthening exercises | Shoulder pain (VAS); CMS; shoulder function (SST); maximum strength; repair integrity according to Sugaya’s classification (MRI) | After 6 months: Pain decreased more in TG (−6.7) compared to CG (−5.0, p <0.001). After 12 months: no differences between groups in CMS (TG: 21.3 ±4.6, CG: 22.6 ±6.6, p = 0.329) and SST (TG: 6.9 ±1.4, CG: 7.0 ±1.9, p = 0.072). The groups were different in terms of repair type (I, II, III) (p = 0.045). | Use of the supplement for 3 months after RC repair decreases postoperative shoulder pain and leads to slight improvement in repair integrity. |
| Notarnicola et al. (2012) [38] | RCT | To assess the clinical efficacy and perfusion effects of oral dietary supplements in association with ESWT for insertional AT tendinopathy | 64 insertional AT tendinopathy patients (55.8 ±13.2 y, 53% male) | Two daily sachets Tenosan (500 mg arginine-L-alpha-ketoglutarate, 550 mg methyl-sulfonyl-methane, 300 mg hydrolyzed collagen type I, 125 mg Vinitrox, 50 mg bromelain, 60 mg vitamin C) for 60 days | ESWT | Placebo + ESWT | Pain (VAS); subjective scores of pain and function and objective scores of physical examination (Ankle-Hindfoot Scale); pain and limitations of activity (Roles and Maudsley score) | VAS scores were lower in TG compared to CG after 2 months (3.9 ±3.2 vs. 5.1 ±2.7, p = 0.07) and 6 months (2.9 ±2.3 vs. 2.0 ±1.8, p = 0.04). Values for the Ankle-Hindfoot Scale were higher in TG compared to CG after 2 months (85 ±12.4 vs. 72.1 ±23.1, p = 0.0035) and 6 months (92.4 ±8.5 vs. 76.5 ±21.6, p = 0.0002). Roles and Maudsley scores were lower in TG compared to CG after 2 months (1.7 ±0.9 vs. 2.8 ±0.4, p <0.0001) and 6 months (1.5 ±0.6 vs. 2.3 ± 0.8, p <0.0001). | Dietary supplement plus ESWT can induce better clinical and functional outcome in AT patients. |
| Baar (2019) [45] | Case study | To determine whether a targeted loading and nutritional program could enhance the outcomes of a PT tendinopathy rehabilitation program | 1 professional basketball player (21 y, male) with PT tendinopathy | 15 g gelatine + 225 mg vitamin C twice a week for 18 months (one hour before every PT targeted training session) | Strength-based rehabilitation program | Pre-measurements | Maximal single-leg isometric hamstring strength; isometric leg extension strength; leg press strength; tendon thickness (MRI) | After 18 months: Increased hamstring (196%), leg extension (156%) and leg press (187%) strength. Thickness of proximal end of the tendon decreased by 25%. Thickness at tendon midpoint increased by 10%. | A nutritional intervention combined with a rehabilitation program can improve clinical outcomes in elite athletes |
| Mavrogenis et al. (2004) [37] | RCT | To evaluate the effect of essential fatty acids, antioxidants and physiotherapy on chronic tendon disorder | 31 active recreational athletes with chronic tendon disorder (TG: 31 y, 76% male; CG: 32 y, 86% male) | 8 capsules/day 376 mg eicosapentaenoic acid (EPA), 264 mg docosahexaenoic acid (DHA) and 672 mg gamma-linolenic acid (GLA) + 1 antioxidant-complex tablet 100 µg selenium, 15 mg zinc, 1 mg vitamin A, 2.2 mg vitamin B6, 90 mg vitamin C and 15 mg vitamin E for 32 days | Physiotherapy (therapeutic ultrasound), 16 sessions x 5 min | Placebo + physiotherapy (as TG) | Pain during sporting activity and after an isometric test (VAS); quantification of sports activity | After 32 days: Pain during sporting activity and after an isometric test decreased more in TG (99%, 99%) compared to CG (31%, 37%, p <0.001). Sports activity increased by 53% in TG and 11% in CG. | Essential fatty acids and antioxidants in combination with physiotherapy have beneficial effects in treating chronic tendon disorders. |
| Sandford et al. (2018) [41] | RCT | To compare the effectiveness of long chain omega-3 polyunsaturated fatty acids (PUFAs) as part of the management for people diagnosed with RC-related shoulder pain | 73 patients with RC-related shoulder pain (TG: 52.2 ±12.0 y, 45% male; CG: 52.0 ±16.2 y, 57% male) | 9 daily capsules MaxEPA (170 mg eicosapentaenoic acid, 115 mg docosahexaenoic acid, 2 units/g tocopherols acetate (vitamin E)) for 2 months | Weekly exercise and education groups for 8 weeks | Placebo (with same amount of vitamin E + antioxidants as TG) + weekly exercise and education groups for 8 weeks | Disability (OSS, SPADI); Pain (NRS, SF-36 bodily pain domain); Quality of life (SF-36, Euro QoL 5D-3 L); Function (PSFS); global perception of change; impairment measures (shoulder range of motion, strength). | Improved OSS scores of 25% in both groups, without differences between groups at 2 (−0.1, p = 0.95) and 12 months (−0.3, p = 0.82). SPADI scores differed only at 3 months between TG (25.3 ±21.1) and CG (13.9 ±18.1). Other outcomes improved in both groups without statistically significant differences between groups. | Omega-3 PUFA supplementation may have a modest effect on disability and pain outcomes in patients with RC-related shoulder pain at 3 months, but not over the course of one year. |
| Farup et al. (2014) [42] | Non-randomized controlled study | To investigate the effect of 12 weeks of either maximal eccentric or concentric resistance training combined with either a high-leucine whey protein hydrolyzate + carbohydrate supplement or placebo, on quadriceps muscle and PT hypertrophy | 22 healthy young recreationally active men (23.9 ±0.8 y) | A drink containing 19.5 g high-leucine (14.2%) whey protein hydrolyzate + 19.5 g carbohydrate (glucose) on all training days (33x in 12 weeks) | Eccentric training with one leg, concentric training with the other leg | Placebo (isoenergetic carbohydrate (glucose)) + training (as TG) | PT CSA (MRI); isometric strength (MVC, RFD) | After 12 weeks: Greater increase in PT CSA at proximal level in TG (14.9 ±3.1%) compared to CG (8.1 ±3.2%, p = 0.054). MVC and RFD increased by 15.6 ±3.5% (p <0.001) and 12-63% (p <0.05) without group effects. | Training-induced hypertrophy of the PT was augmented with a high-leucine whey protein hydrolyzate supplement. |
| Saggini et al. (2010) [40] | RCT (two-arm) | To evaluate the efficacy of a specific rehabilitative, therapeutic protocol integrated with administration of a supplement in both conservative rehabilitation treatment and post-surgery, in patients with RC lesions | Arm A: 30 RC lesion patients, treated conservatively (45 ±10 y, 37% male). Arm B: 50 RC lesion patients, treated conservatively (59.5 ( | 1 sachet/day 3.5 g Amedial BF (glucosamine sulfate, chondroitin sulfate, hydrolyzed type II collagen, hydrolyzed hyaluronic acid, L-carnitine fumarate) for 1 month (Arm A) for 60 days (Arm B) | Arm A: 3 shock waves + 9 sittings Multi Joint System; Arm B: rehabilitation treatment | Arm A: 3 shock waves + 9 sittings Multi Joint System (CG1) or 3 shock waves (CG2); Arm B: rehabilitation treatment | Arm A: ROM; pain (VAS); Arm B: UCLA (pain, functionality, active frontal flexion, strength in frontal flexion, satisfaction) | Arm A, after 1 month: VAS scores reduced by 45% in TG, 22% in CG1 and 45% in CG2. Flexion, extension, abduction and external rotation increased by 38%, 57%, 47% and 52% in TG, 28%, 40%, 42% and 40% in CG1 and 26%, 23%, 36% and 25% in CG2. Arm B, after 60 days: Higher improvement in TG compared to CG for pain (73% vs. 70%), function (49% vs. 36%), flexion (41% vs. 29%) and strength (39% vs. 30%) scores. Satisfaction was higher in TG (92%) than in CG (84%). | Supplementation of natural substances is a conservative treatment for RC lesions to consider. Quicker functional recovery with post-surgical supplementation. |
| Schneider et al. (2009) [46] | Case series | To identify characteristics associated with bilateral ruptures of the distal biceps tendons | 10 patients with sustained non-simultaneous bilateral distal biceps brachii tendon ruptures, surgically repaired (49.5 (27.7-76.2) y, male) | Nutritional supplements (multivitamins and omega 3 oils) | NA | NA | Disability (DASH) | DASH scores were not significantly related to using nutritional supplements at the time of injury (p = .145) | No correlation found between outcome following surgical treatment and use of nutritional supplements. |
| Szczurko et al. (2009) [28] | RCT | To evaluate the potential for the combined efficacy of a naturopathic approach including acupuncture, dietary advice and hydrolytic enzymes in the treatment of RC tendinitis | 85 Canadian postal employees with RC tendinitis (TG: 50.7 ±8.16 y, 42% male; CG: 50.9 ±7.86 y, 40% male) | 6 tablets/day of Phlogenzym (90 mg bromelain, 48 mg trypsin, 100 mg rutin) + patient-customized dietary counseling, with special emphasis on reducing alcohol consumption and increasing consumption of fish, berries, fruits, vegetables, nuts, and whole grains for 12 weeks | Acupuncture | Placebo + physical exercise | Disability (SPADI); health-related QoL (SF-36); pain over the last week (VAS); patient experiences (MYMOP); flexion, extension, abduction, adduction, internal rotation and external rotation of affected shoulder | After 12 weeks: SPADI scores improved more in TG (54.5%) compared to CG (18%, p <0.0001). TG also showed superiority in SF-36, VAS, MYMOP scores and range of motion. | Naturopathic treatments including dietary changes, acupuncture and Phlogenzym have a significant effect on decreasing RC tendinitis symptoms. |
AT, Achilles tendon; CG, control group; CMS, Constant-Murley score; CSA, cross-sectional area; DASH, Disabilities of Arm, Shoulder, and Hand; ESWT, Extracorporeal Shock Wave Therapy; LET, lateral epicondyle tendon; MEPS, Mayo Elbow Performance Score; MMYOP, Measure Yourself Medical Outcomes Profile; MRI, magnetic resonance imaging; MVC, maximal voluntary contraction; NRS, Numerical Rating Scale; OSS, Oxford Shoulder Score; PRTEE, Patient-rated Tennis Elbow Evaluation; PSFS, Patient-Specific Functional Scale; PT, patellar tendon; RC, rotator cuff; RCT, randomized controlled trial; RFD, rate of force development; SF-36, Short-Form Health Survey; SPADI, Shoulder Pain and Disability Index; SSP, supraspinatus; SST, Simple Shoulder Test; TG, treatment group; RC, rotator cuff; VAS, Visual Analogue Scale; VISA-A, Victorian Institute of Sports Assessment – Achilles questionnaire; VISA-P, Victorian Institute of Sports Assessment – Patellar questionnaire; USI, ultrasound imaging.
Overall quality judgment of each study assessed by the RoB 2 tool.
| Author | Overall Risk of Bias Judgment* | Main Sources of Bias |
|---|---|---|
| Balius et al. [ | Some concerns | No placebo treatment |
| Gumina et al. [ | Some concerns (high) | No placebo treatment |
| Mavrogenis et al. [ | Some concerns (high) | No intention-to-treat analyses |
| Merolla et al. [ | Some concerns | Mainly participant-reported outcomes |
| Notarnicola et al. [ | Low risk (some concerns) | No baseline characteristics presented |
| Praet et al. [ | Some concerns (high) | No wash-out period |
| Saggini et al. [ | High risk | Insufficient information about randomization, group comparison, protocol and analyses |
| Sandford et al. [ | Low risk | |
| Szczurko et al. [ | Some concerns | High drop-out rate |
*Possible judgments are: Low risk, Some concerns, High risk
Overall quality judgment of each study assessed by the ROBINS-I tool.
| Author | Overall Risk of Bias Judgment* | Main Sources of Bias |
|---|---|---|
| Arquer et al. [ | Serious | No control group |
| Baar [ | Serious | One participant |
| Farup et al. [ | Low | Small study population |
| Hjerrild et al. [ | Serious | Cross-sectional design |
| Jain, et al. [ | Moderate/Serious | Small study population |
| Owens et al. [ | Moderate | Not all confounders were taken into account |
| Passaretti et al. [ | Serious | Potential of selection bias |
| Rechardt et al. [ | Moderate | Cross-sectional design |
| Schneider et al. [ | Critical | Small study population |
| Vitali et al [ | Moderate | No placebo |
*Possible judgments are: Low, Moderate, Serious, Critical
Table 1 Core domains of tendinopathy as defined by the ICON group [2019, 23].
| Domain | Description/definition | Example outcome |
|---|---|---|
| Patient rating of condition | A single assessment numerical evaluation | Rate your tendon status where 100% is no problems and 0% worst case scenario, global rating of change, patient acceptable symptom status |
| Participating in life activities | Patient rating of the level of participating | Ratings of level of sport and time to return to sport |
| Pain on activity/loading | Patient reported intensity of pain on performing a task/activity that loads the tendon | VAS or NRS for pain intensity when the patient performs a tendon-specific pain-provocative task |
| Function | Patient rated level of function (and not referring to the intensity of their pain) | Patient Specific Function Scale on a VAS or NRS |
| Psychological factors | Psychology | Pain self-efficacy, pain catastrophisation, kinesiophobia, anxiety or depression scales |
| Physical function capacity | Quantitative measures of physical tasks performed in clinic | Number of hops, timed stair walk, number of single limb squats, including dynamometry and wearable technology |
| Disability | Composite scores of a mix of patient-rated pain and disability due to the pain, usually to tendon-specific activities/tasks | VISA scales, patient-rated tennis elbow evaluation, disability of the arm, shoulder and hand |
| Quality of life | The general well-being of the individual | Specific QoL questionnaires such as European QoL – 5 Dimension (EQ-5D) Australian QoL (AQoL), 36-item Short Form survey (SF-36) |
| Pain over a specified time | Participant reported pain intensity over a period of time (morning, night, 24 hours, a week) | VAS, NRS |
Table 2 Search strategy in PubMed.
| Concept | Search terms |
|---|---|
| Tendinopathy | (((‘Tendinopathy’[Mesh] OR tendinopathy[tiab] OR tendinopathies[tiab] OR tendinosis[tiab] OR tendinoses[tiab] OR tendinitis[tiab] OR tendonitis[tiab] OR tendonosis[tiab] OR tendonitides[tiab] OR ‘Tendon Injuries’[Mesh] OR tendon injuries[tiab] OR tendon injury[tiab] OR tendon healing[tiab] OR tendon disorder*[tiab] OR tendon repair[tiab]) OR ((‘Tendons’[Mesh] OR tendon*[tiab]) AND (‘prevention and control’ [Subheading] OR prevention[tiab] OR preventive therapy[tiab]))) |
| Nutrition | AND (curcumin[tiab] OR boswellic acid[tiab] OR arginin*[tiab] OR tendisulfur[tiab] OR bromelain[tiab] OR methylsulfonylmethane[tiab] OR ‘Amino Acids, Peptides, and Proteins’[Mesh] OR amino acid[tiab] OR protein[tiab] OR proteins[tiab] OR leucine[tiab] OR glutamine[tiab] OR arginine[tiab] OR taurine[tiab] OR gelatin[tiab] OR ‘Collagen’[Mesh] OR collagen[tiab] OR ‘Phytochemicals’[Mesh] OR phytochemicals[tiab] OR phytonutrients[tiab] OR ‘coenzyme Q10’[Supplementary Concept] OR coenzyme Q10[tiab] OR co-enzyme Q10[tiab] OR ‘Fatty Acids, Omega-3’[Mesh] OR omega 3[tiab] OR omega-3[tiab] OR ‘Lipids’[Mesh] OR lipids[tiab] OR fatty acids[tiab] OR fish oils[tiab] OR plant oils[tiab] OR ‘Nutrition Therapy’[Mesh] OR nutrition therapy[tiab] OR diet therapy[tiab] OR nutrient intake[tiab] OR ‘Nutrients’[Mesh] OR nutrient*[tiab] OR macronutrient*[tiab] OR ‘Diet, Food, and Nutrition’[Mesh] OR nutrition[tiab] OR ‘Micronutrients’[Mesh] OR micronutrient*[tiab] OR vitamin*[tiab] OR ‘Ascorbic Acid’[Mesh] OR ascorbic acid[tiab] OR vitamin c[tiab] OR antioxidant*[tiab] OR ‘Vitamin D’[Mesh] OR vitamin d[tiab] OR cholecalciferol[tiab] OR ergocalciferols[tiab] OR ‘Minerals’[Mesh] OR minerals[tiab] OR calcium[tiab] OR manganese[tiab] OR copper[tiab] OR zinc[tiab] OR magnesium[tiab] OR iron[tiab] OR molybdenum[tiab] OR silicon[tiab] OR calories[tiab] OR ‘Dietary Supplements’[Mesh] OR dietary supplement*[tiab] OR food supplement*[tiab] OR food additives[tiab] OR fortified food[tiab] OR nutraceutical[tiab] OR nutritional[tiab] OR ‘Glycerol’[Mesh] OR glycerin[tiab] OR glycerol[tiab])) |
| Human | NOT ((animals[mh] NOT (animals[mh] AND humans[mh])) NOT rat[tiab] NOT rats[tiab] NOT mice[tiab] NOT rabbit*[tiab]) |
Table 3 Rating of the certainty of evidence for clinical outcomes.
| GRADE domain | Judgment | Concerns about certainty domains |
|---|---|---|
| Methodological limitations of the studies | Among the nine RCTs, the majority expressed ‘some concerns’ with respect to the risk of bias. Two studies were judged at low risk of bias and one study had a high risk of bias. The risk of bias of the remaining five intervention and observational studies was judged at low or moderate for two studies, and serious or critical for three studies. Main aspects that raise concerns were reporting participant-reported outcomes, incomplete or unclear reporting of methods or results, and small study populations. Therefore, we judged the studies to have serious methodological limitations. | Serious |
| Indirectness | Most studies were primarily aimed to investigate the effect of the dietary supplement on clinical outcomes, but often in combination with other treatments. We judged the evidence to have moderate indirectness. | Moderate |
| Imprecision | The total number of participants included in all studies was 819. We judged the evidence to have moderate imprecision. | Moderate |
| Inconsistency | The majority of the studies found a beneficial effect of the supplement intake on one or more of the clinical outcomes. There is inconsistency in the effects on different time points, but this could be addressed by variation in study protocol. We judged the evidence to have moderate inconsistency. | Moderate |
| Publication bias | Some studies are commercial studies. We found no commercial studies without effect. | Potential |
Table 4 Rating of the certainty of evidence for occurrence/prevalence of tendinopathy.
| GRADE Domain | Judgment | Concerns About Certainty Domains |
|---|---|---|
| Methodological limitations of the studies | The risk of bias was judged at moderate for two out of three studies. One study was judged at serious risk of bias, but this study was smaller compared to the other two (605 vs. 80,106/6237). All studies had an observational design, which involves several limitations. In addition, sources of bias were inappropriate statistical adjustments, potential underreporting of intake and incomplete reporting of results. Therefore, we judged the studies to have serious methodological limitations. | Serious |
| Indirectness | Only one study primarily aimed to investigate the association between the intake of alcohol and the risk of tendinopathy. In the other two studies, alcohol consumption was only one of many factors that were investigated to find an association. One study did not even report data with regard to alcohol consumption. Therefore, we judged the evidence to have serious indirectness. | Serious |
| Imprecision | The total number of participants included in all studies was 86,948. This is a large number, but this is mainly due to one large cohort study with relatively low number of cases identified. We judged the evidence to have moderate imprecision. | Moderate |
| Inconsistency | The studies reported either a positive association or no association between alcohol consumption and the risk of tendinopathy. One study found a marginal association for moderate weekly alcohol consumption and Achilles tendinopathy, but not for heavy weekly alcohol consumption or patellar tendinopathy. Another study found significant risks of rotator cuff tears for excessive drinkers. We judged the evidence to have moderate inconsistency. | Moderate |
| Publication bias | We do not suspect publication bias, taking into account that we have few studies | Not suspected |
Table 5 Summary of findings regarding the GRADE judgments.
| Outcome | Effect | Number of Participants (Studies) | Certainty in the Evidence |
|---|---|---|---|
| Clinical outcomes | Most studies showed positive effects on one or more clinical outcomes, or found no significant effects | 819 (14 experimental studies including 9 RCTs) | |
| Occurrence/prevalence of tendinopathy | Two studies found a positive association between alcohol consumption and risk of tendinopathy. One study showed no association. | 86,948 (3 observational studies) |